Matching Geography

Reports matching your search in:
 
 

Research Assistance

 

Free Alert Me service

Receive bi-weekly email alerts on new market research

Sign Up Today!
 

Parkinson's Disease

1594

A disease of the motor system, generally, PD affects people over the age of 50. Early symptoms of PD are subtle and occur gradually. In some people the disease progresses more quickly than in others. Symptoms of Parkinson’s Disease would be tremor in body or trembling in hands, arms, legs, jaw, and face; rigidity, or stiffness of the limbs and trunk; slowness of movement or impaired balance and coordination.
These are very visible symptoms, and patients may have difficulty walking, talking, or completing other simple tasks.

As the disease progresses, the shaking, or tremor, which affects the majority of PD patients may begin to interfere with daily activities. Other symptoms may include depression and other emotional changes; difficulty in swallowing, chewing, and speaking; urinary problems or constipation; skin problems; and sleep disruptions. There are currently no blood or laboratory tests that have been proven to help in diagnosing sporadic PD. Therefore the diagnosis is based on medical history and a neurological examination. The disease can be difficult to diagnose accurately.

There is no cure for PD, but a variety of medications provide dramatic relief from the symptoms. Usually, patients are given levodopa combined with carbidopa. Carbidopa delays the conversion of levodopa into dopamine until it reaches the brain. Anticholinergics may help control tremor and rigidity. Other drugs, such as bromocriptine, pramipexole, and ropinirole, mimic the role of dopamine in the brain, causing the neurons to react as they would to dopamine. An antiviral drug, amantadine, also appears to reduce symptoms.

RSS Feeds

All reports in Parkinson's Disease

< prev 1  2  next >
Parkinson's Disease Therapeutics - Global Drug Forecasts and Treatment Analysis to 2020
1/31/2012 | published by: GlobalData
... The report is an essential source of information and analysis on the global Parkinson’s Disease (PD) therapeutics market. It provides comprehensive market information, highlighting the treatment guidelines and identifying and analyzing the key trends shaping ...  |  more...
$6,995.00
Parkinson's Disease - Pipeline Review, H1 2012
1/23/2012 | published by: Global Markets Direct
... for Parkinson's Disease, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Parkinson's Disease. 'Parkinson's Disease - Pipeline Review, H1 2012' ...  |  more...
$500.00
Parkinson's Disease Global Clinical Trials Review, H2, 2011
10/30/2011 | published by: GlobalData
... and data relating to the clinical trials on Parkinson’s Disease. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers ...  |  more...
$1,000.00
Parkinson's Disease: World Drug Market 2011-2021
9/26/2011 | published by: Visiongain
... world, submarket, product and national levels to 2021? Through our research and analysis we aim to save you time and help in your decisions. Find out how the drugs Stalevo/Comtess, Sifrol, Azilect and Requip can ...  |  more...
$2,642.00
Parkinson's Disease - Pipeline Review, Q3 2011
7/31/2011 | published by: Global Markets Direct
... for Parkinson's Disease, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Parkinson's Disease. 'Parkinson's Disease - Pipeline Review, Q3 2011' ...  |  more...
$500.00
The 10th International Conference on Alzheimer's and Parkinson's Diseases: Post-Conference Review and Analysis
3/31/2011 | published by: GlobalData
... conference alert is an essential source of information and analysis on the emerging therapies and new disease management techniques. The annual meeting of the 10th International Conference on Alzheimer’s and Parkinson’s Diseases was held in ...  |  more...
$1,000.00
The Michael J. Fox Foundation for Parkinson's Research-Detailed Product Pipeline
3/14/2011 | published by: Life Science Analytics (LSA)
... reports Accessing accurate, current and comprehensive content on global public and private pipeline companies can be challenging however, Life Science Analytics has created a suite of reports that deliver the latest information on over 2,500 ...  |  more...
$750.00
Parkinson Disease Therapy Area Pipeline Report
3/14/2011 | published by: Life Science Analytics (LSA)
... as well as a summary of the latest news and developments in this area. Scope of the report: Each Life Science Analytics’ Therapy Area Pipeline Report provides the user with real detail on drug pipelines, ...  |  more...
$1,495.00
The Michael J. Fox Foundation for Parkinson's Research-Deals & Alliances Report
3/14/2011 | published by: Life Science Analytics (LSA)
... stage of development, list of partners, deal types (licensing, marketing, etc.), top deals by deal value, partners based on technology with detailed descriptions of the partner firm where disclosed, partners based on product with detailed ...  |  more...
$600.00
Novel Targeted Therapies Hold the Promise of Cure for Parkinson's Disease (PD)
2/28/2011 | published by: GlobalData
... of Parkinson’s Disease and how the novel pipeline molecules will drive the global market Scope Data and information on noval therapy on Parkinson’s Disease market Reasons to buy Develop business strategies by understanding the trends ...  |  more...
$500.00
Parkinson's Disease - Pipeline Review, Q1 2011
1/24/2011 | published by: Global Markets Direct
... for Parkinson's Disease , complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Parkinson's Disease . 'Parkinson's Disease - Pipeline Review, ...  |  more...
$500.00
Epidemiology: Parkinson's Disease
1/10/2011 | published by: Datamonitor
... in the US. Incidence rates are expected to remain constant, while total prevalence rates will increase as a result of the aging population in the seven major markets. Features and benefits Gain insight to market ...  |  more...
$5,700.00
Parkinson Disease Therapy Pipeline Report
1/6/2011 | published by: Life Science Analytics (LSA)
... drugs by company and by stage as well as a summary of the latest news and developments in this area. Scope of the report: Each Life Science Analytics’ Therapy Area Pipeline Report provides the user ...  |  more...
$1,495.00
Parkinson's Disease Global Clinical Trials Review, Q4, 2010
12/30/2010 | published by: GlobalData
... and data relating to the clinical trials on Parkinson’s Disease. It includes an overview of the trial numbers and their recruitment status as per the site of trial development throughout the world, focusing on the ...  |  more...
$1,000.00
Pipeline and Commercial Insight: Parkinson's Disease - Reformulations sustain market growth in the absence of therapeutic breakthroughs
12/17/2010 | published by: Datamonitor
... to 2.2% (2009-19), as pipeline entries partially offset the generic erosion of key brand sales. Features and benefits Quantify the historic (2005-09) and future (2010-19) size of the Parkinson’s disease market. Comprehensive epidemiology review of ...  |  more...
$15,200.00
Parkinson's Disease Market Forecast
12/16/2010 | published by: Datamonitor
... to 2.2% (2009-19), as pipeline entries partially offset the generic erosion of key brand sales. Features and benefits Quantify the future (2010-19) size of the Parkinson’s disease market. Review of the current Parkinson's disease drug ...  |  more...
$15,200.00
Stem Cell Market: Opportunities and Challenges
12/1/2010 | published by: Koncept Analytics
... as Parkinson’s disease, diabetes, heart diseases and cancer as well as injuries for which there has previously been no effective treatment. The medical stem cells market is divided into three categories: stem cell therapeutics, cord ...  |  more...
$800.00
Neurodegenerative Drugs
4/1/2010 | published by: Global Industry Analysts
... analytics for the US, Europe, and Rest of World. Annual estimates and forecasts are provided for each region for the period 2006 through 2015. The report profiles 165 companies including many key and niche players ...  |  more...
$3,950.00
Global Neuromodulation Market 2009-2013
2/24/2010 | published by: Infiniti Research Limited
... ailments and psychiatric illnesses. It is widely used for the treatment of chronic conditions such as lower back pain, urinary incontinence, Parkinson's disease, tremor, epilepsy, depression, etc. Advancement in technology and greater knowledge in neurophysiology ...  |  more...
$1,500.00
What's Next in Vaccines? HIV, Malaria, MRSA, and 30 Other Vaccine Targets in the 2010-2016 Pipeline
2/1/2010 | published by: Kalorama Information
... illnesses may see a vaccine option in the coming years? Which vaccines will have the most successful business model? Who are the major companies in this market, and possible new entrants? What can current vaccine ...  |  more...
$4,200.00
The Neurodiagnostics Report 2010: Brain Imaging, Biomarkers and NeuroInformatics
1/15/2010 | published by: NeuroInsights, LLC
... system disorder including addiction, Alzheimer’s, depression, anxiety, schizophrenia, attention disorders, epilepsy, Parkinson’s disease, sensory disorders, and sleep disorders. Diagnosis of these disorders is rapidly changing as new tools are developed for more objective and personalized ...  |  more...
$2,995.00
Central Nervous System Parkinson Disease Therapy Area Pipeline Report
1/7/2010 | published by: Life Science Analytics (LSA)
... as well as a summary of the latest news and developments in this area. Scope of the report: Each Life Science Analytics’ Therapy Area Pipeline Report provides the user with real detail on drug pipelines, ...  |  more...
$1,495.00
World Neurodegenerative Diseases Market 2009-2024
9/18/2009 | published by: Visiongain
... Increasing disease prevalence and a robust pipeline make that sector dynamic and highly promising for pharmaceutical and biotechnology companies worldwide. Our new report - World Neurodegenerative Diseases Market 2009-2024 - explains why, revealing where the ...  |  more...
$2,331.00
European Markets for Parkinson's Disease Therapeutics
5/30/2009 | published by: Frost & Sullivan
This research service discusses the market for Parkinson's disease. It analyses the various opportunities, recent developments, drug classes and gives a revenue forecasts.  |  more...
$6,500.00
The 2009-2014 World Outlook for Drugs for Alzheimer's and Parkinson's Diseases
1/8/2009 | published by: Icon Group International, Inc.
... for the country in question (in millions of U.S. dollars), the percent share the country is of the region and of the globe. These comparative benchmarks allow the reader to quickly gauge a country vis-à-vis ...  |  more...
$795.00
< prev 1  2  next >